Open Journal Systems

Clinical Study on Adjuvant Chemotherapy of Cinobufacin Injection in Senior Patients with Colorectal Cancer

Shupeng Wang (The Fourth People's Hospital of Shenyang City, Shenyang, China)


To investigate the clinical efficacy of adjuvant chemotherapy of cinobufacin injection in the treatment of senior patients with colorectal cancer and its influence on serum tumor markers and immune function, from November 2018 to November 2019, 84 senior colorectal cancer patients in author's hospital were al randomly divided into control group and observation group, 42 cases in each group, and the control group was treated with routine chemotherapy, the observation group was treated with routine chemotherapy and intravenous injection of cinobufacin, the two groups were all treated for 4 cycles, then the short-term efficacy, serum tumor markers [carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 724 (CA724 ), carcinoembryonic antigen (CEA)] and immune function indexes (CD3+, CD4+, CD4+/CD8+), as well as the unward reaction of chemotherapy were compared between the two groups before and after treatment. As results, Short-term efficacy: the total effective rate of observation group was significantly higher than that of control group (78.57%vs 47.62%, P <0.05). Tumor markers: after treatment, the levels of CA19-9, CA724 and CEA in the two groups were significantly lower than those before treatment (P <0.05). Compared between the two groups, the levels of each index in observation group were lower ( P <0.05). Immune function after treatment the levels of CD3+, CD4+, CD4+/CD8+ in observation group were significantly higher than those before treatment while the levels of CD3+, CD4+,  CD4+/CD8+ in control group were significantly lower (P <0.05). After treatment, the above each index in observation group were higher than those in control group (P <0.05). Untoward reaction: the incidence of leukopenia, thrombocytopenia, gastrointestinal response, fatigue and myelosuppresion in observation group were significantly lower than those in control group (P <0.05). The results show that cinobufacin injection in the adjuvant treatment of senior patients with colorectal cancer can improve the short-term efficacy of chemotherapy, reduce the untoward reaction, and reduce the serum levels of CA19-9, CA724 and CEA, improve the immune function of the body, thus with high clinical application value. 


Colorectal cancer; Senior; Chemotherapy; Cinobufacin injection; Short term efficacy; Tumor

Full Text:



Huang Jinlin, Liu Xiaohua. Huabamin injection combined with chemotherapy in the treatment of recurrence and metastasis

Clinical observation of colorectal carcinoma [J]. Clinical Medicine, 2012,32 (12): 56-57.

ZOU Y. A prospective study on the improvement of adverse reactions of postoperative chemotherapy in colorectal cancer [D]. Shanghai: Shanghai University of Traditional Chinese Medicine, 2017.

Wang Y, Wang Y, Wang Y, et al. Clinical significance of colorectal cancer in China [J]. Chinese Journal of Gastrointestinal Surgery, 2018,21 (1):92-106.

Li Junkui, Han Hui. Study on the clinical efficacy of traditional Chinese medicine in the prevention and treatment of cancer after chemotherapy [J]. Inner Mongolia Journal of Traditional Chinese Medicine, 2016,35 (12):124-125.

Gong Z P, Chen T, Deng L R, et al. Research progress of antitumor clinical application of Huabenin injection combined with chemotherapy [J]. Anhui Medical Journal, 2010,14 (1):12-14.

Bo J, Chen X H, Wang H C, et al. The value of serum CEA, CA19-9 and PET-CT SUVs in the diagnosis of postoperative recurrence/metastasis in patients with colorectal cancer [J]. J Clin Endocrinol, 2010, 35 (1) : 79-84. Progress in Modern General Surgery in China, 2016,19 (4): 326-327,330.

Fang Jingyuan, Yu Yanan, Lin Yanwei. Common shadow of intestinal microecology and mucosal immunity[J]. Colorectal Cancer, 2013,33 (12):811-813. (in Chinese with English abstract)



  • There are currently no refbacks.

Copyright (c) 2020 Shupeng Wang

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.